ROSG....
We currently have the following distribution agreements relating to our diagnostic tests:
• with Teva Pharmaceutical Industries Ltd., pursuant to which Teva has the right to distribute these tests in Turkey and Israel;
>As a leading specialty pharmaceuticals innovator, Teva develops and manufactures innovative pharmaceutical products in niche specialty areas: CNS, respiratory, women's health, oncology, biosimilars and pain. Additionally, Teva continues to strengthen its innovative pipeline, focusing on novel treatments for neurological disorders, autoimmune diseases and oncological diseases.
Biopharmaceuticals
Teva’s Biopharmaceuticals products provide critical and unique therapeutic solutions to a broad range of severe and often life-threatening diseases.
Oncology
Teva Oncology is dedicated to improving the lives of people with cancer, through a portfolio of marketed products as well as continued investment in the development of novel oncology therapeutics.
• with Warnex Medical Laboratories, a division of Warnex, Inc., pursuant to which Warnex has the exclusive right to distribute these tests in Canada;
• with Genekor S.A., pursuant to which Genekor has the exclusive right to distribute these tests in Greece;
• with Super Religare Laboratories Limited (SRL), pursuant to which SRL has the non-exclusive right to distribute these tests in India, Saudi Arabia, Qatar and the United Arab Emirates;
> Super Religare Laboratories (SRL), is the veritable pioneer of medical diagnostics in India. Established in 1995, within 17 years from inception, SRL has been imbued with a mission to deliver Gold Standard Diagnostic services, both in the field of radiology and pathology.
SRL is the only Pathology Lab Network in India to have 8 Reference Labs, 8 centres of excellence, over 200 network laboratories, 19 radiology/imaging centres, and a Footprint spanning over 1250 Collection Centres, offering more than 4000 test. Today SRL is conducting more than 50,000 tests in a day ranging from simple test to high-end tests. Through its network of laboratories, SRL offers the most comprehensive range of diagnostic facilities that cover an extensive range of specialties. Apart from pathology services SRL also provides a complete range of radiology modalities including Computed Tomography (CT), Diagnostic Radiology (X- Ray), Magnetic Resonance Imaging (MRI), Ultrasound and Positron Emission Tomography (“PET”).
One of the pathology company to have dedicated R&D division and ISO certified and recognized by the Government of India‘s Department of Scientific and Industrial Research. SRL’s wide range of tests provides quality diagnostic, prognostic and monitoring services to other path labs, hospitals and patients. It also provides clinical research services by conducting Phase I- IV clinical trials for multinational and Indian pharmaceutical and biotechnological companies, thereby supporting their international regulatory submissions.
• with Genetic Technologies Limited (GTL), pursuant to which GTL has the exclusive right to distribute these tests in Australia, New Zealand and Singapore.
>Genetic Technologies (ASX: GTG, NASDAQ Capital Market: GENE) is leading-edge genetic testing business which, together with an extensive range of international patents and allied research activities, aims at uncovering the impact of DNA on health.
Throughout the Asia Pacific region, we translate specialized genetic tests into products and services that optimize the health knowledge and outcomes in humans, animals and plants.
In addition, in October 2011, we entered into a license agreement with Avatao Biotech pursuant to which we granted Avatao exclusive rights to market and perform our miRview ® mets and miRview ® mets2 tests in China. Avatao will also have exclusive rights to market and perform one additional test in China, to be selected by Avatao within one year. However, as of May 15, 2012, we believe Avatao Biotech is in breach of the license agreement for failure to make required payments to us, and we are currently exploring our options due to this breach, including potentially terminating the agreement.
We are largely dependent upon these distributors for the commercial success of our tests outside of the United States. The potential revenues from these agreements consist of contingent payments based on the sale of our products. These payments will depend upon our collaborators’ ability to devote the necessary resources to successfully commercialize these tests. In addition, if any of our current or potential future distributors were to breach or terminate its agreement with us, the commercialization of these tests could be adversely affected because we may not have sufficient financial resources or capabilities to successfully commercialize these tests on our own or find other partners.
AI
